Roche cobas HPV检测用于头颈鳞癌细胞学标本及无细胞上清液的高危HPV状态判定
本研究评估Roche cobas 4800平台在头颈鳞癌细针穿刺(FNA)细胞沉淀及无细胞上清液中检测高危HPV(hrHPV)的性能,并与组织p16免疫组化比较。细胞沉淀和上清液灵敏度均为100%,特异性分别为94.7%和100%。上清液检测可准确判定HPV状态并节省细胞形态学分析材料。
要点
- cobas检测细胞沉淀与上清液hrHPV均与p16免疫组化高度一致。
- 上清液检测灵敏度100%、特异性100%,细胞沉淀特异性94.7%。
- 使用无细胞上清液可保留细胞块材料用于形态学分析。
核心结论
- cobas hrHPV检测头颈鳞癌标本与p16免疫组化高度一致。
- 无细胞上清液检测可提供准确HPV结果并节省细胞材料。
研究设计与样本
- 前瞻性评估Roche cobas 4800平台在FNA细胞沉淀及对应无细胞上清液中的性能。
- 共41份样本(23原发瘤、18淋巴结转移)来自34例头颈鳞癌患者。
- 以组织p16免疫组化为对照,不一致病例用hrHPV RNA原位杂交裁定。
主要发现
- 23份样本(56%)p16免疫组化阳性。
- 2份上清液cobas结果不确定。
- 1份cobas阳性细胞沉淀经RNA原位杂交判定为假阳性。
- cobas灵敏度细胞沉淀和上清液均为100%,特异性分别为94.7%和100%。
关键数值与推荐
- 原发瘤部位包括口咽20份、口腔13份、喉3份、皮肤3份,2例原发灶未明。
- cobas检测细胞沉淀灵敏度100%、特异性94.7%。
- cobas检测无细胞上清液灵敏度100%、特异性100%。
临床怎么用
- FNA标本可选用cobas平台检测hrHPV以辅助头颈鳞癌分型。
- 优先使用无细胞上清液检测,保留细胞沉淀用于形态学分析。
- cobas结果与p16免疫组化一致性高,可作为补充检测。
局限性
- 样本量较小(41份样本、34例患者)。
- 2份上清液cobas结果不确定,1份细胞沉淀假阳性。
- 原发灶部位多样且2例原发灶未明,可能影响普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-risk human papillomavirus-positive (hrHPV+) oropharyngeal squamous cell carcinomas comprise a subset of head and neck squamous cell carcinomas (HNSCCs) with a distinct biology and prognosis. Commonly, the diagnosis of HNSCC is rendered on fine-needle aspiration (FNA). Because cell blocks may be insufficient for determining HPV status using microscopy-based techniques, the ability of liquid-based assays was examined in the current study. METHODS: The performance of the Roche cobas 4800 platform was evaluated on the FNA material from the cell pellet and corresponding cell-free supernatant fluid specimens of primary and metastatic HNSCCs. These results were compared with the p16 immunostain result from the histologic material obtained from the same patient. Discrepant cases were adjudicated using hrHPV RNA in situ hybridization. RESULTS: A total of 41 samples (23 primary tumors and 18 lymph node metastases) were acquired from 34 patients with HNSCC. Primary tumors included the oropharynx (20 samples), oral cavity (13 samples), larynx (3 samples), and skin (3 samples). In 2 cases, a primary tumor could not be identified. Twenty-three samples (56%) were found to be p16 positive by immunohistochemistry. Twenty-two samples were found to be positive on cobas hrHPV testing from both cell pellet and cell-free supernatant fluid. Two cell-free supernatant fluid specimens yielded indeterminate cobas results. At the time additional hrHPV RNA in situ hybridization analysis was performed, one cobas-positive cell pellet was deemed to be a false-positive result. The sensitivity of the cobas assay was 100% for pellet material and cell-free supernatant fluid, with specificities of 94.7% and 100%, respectively. CONCLUSIONS: cobas hrHPV testing of HNSCC specimens demonstrated high concordance with p16 immunohistochemistry on the corresponding cell block and/or tissue specimen. Using the cell-free supernatant fluid in this platform could provide accurate HPV results while conserving material for cytomorphologic analyses.
引用
- Wright MF, Weiss VL, Lewis JS, et al. Determination of high-risk HPV status of head and neck squamous cell carcinoma using the Roche cobas HPV test on cytologic specimens and acellular supernatant fluid. Cancer Cytopathol. 2020. PMID: 32129949. doi:10.1002/cncy.22258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。